DRS

Shockwave Reducer Demonstrates Consistent, Positive Results in ‘Real-World’ Study

Retrieved on: 
Lundi, avril 8, 2024
Observational study, Cardiovascular disease, University Medical Center, Patient, Angina, Șaeș, CCS, American College, University Medical Center Utrecht, DRS, Royal Brompton Hospital, MACE, Pharmaceutical industry

These findings confirm the positive, ‘real-world’ outcomes of Shockwave Reducer, a novel technology for the treatment of refractory angina.

Key Points: 
  • These findings confirm the positive, ‘real-world’ outcomes of Shockwave Reducer, a novel technology for the treatment of refractory angina.
  • Results were presented earlier today at the 73rd Annual Scientific Sessions of the American College of Cardiology in Atlanta, GA.
    REDUCER-I is a post-market, multi-center, observational study designed to collect long-term outcomes on Shockwave Reducer in a large, ‘real-world’ population of 400 patients.
  • “Results from the REDUCER-I study continue to demonstrate the safety and effectiveness of Shockwave Coronary Sinus Reducer as a novel therapy for refractory angina,” said Dr. Verheye.
  • Results from COSIRA-II are intended to support the regulatory filing for US FDA approval of Shockwave Reducer.

NuCana Announces Plan to Implement ADS Ratio Change

Retrieved on: 
Mercredi, mars 27, 2024
Tax, Sale, ADS, DTC, DRS, Depository Trust Company, NCNA, Effective date, Depositary, American depositary receipt, Security (finance)

EDINBURGH, United Kingdom, March 27, 2024 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced plans to change the ratio of its American Depository Shares (“ADSs”) to its ordinary shares from one (1) ADS, representing one (1) ordinary share, to one (1) ADS representing twenty-five (25) ordinary shares (the "ADS Ratio").

Key Points: 
  • EDINBURGH, United Kingdom, March 27, 2024 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced plans to change the ratio of its American Depository Shares (“ADSs”) to its ordinary shares from one (1) ADS, representing one (1) ordinary share, to one (1) ADS representing twenty-five (25) ordinary shares (the "ADS Ratio").
  • The change in the ADS Ratio is expected to become effective on or about April 16, 2024 (the "Effective Date").
  • For the Company's ADS holders, the change in the ADS Ratio has the same effect as a one-for-twenty-five reverse ADS split and will have no impact on an ADS holder’s proportional equity interest in the Company.
  • As a result of the change in the ADS Ratio, the ADS trading price is expected to increase proportionally, although the Company can give no assurance that the ADS trading price after the change in the ADS Ratio will be proportionally equal to or greater than the previous ADS trading price prior to the change or that the change in the ADS Ratio will have any effect on the liquidity in the Company’s ADSs.

The Dr. N. Joyce Payne Center for Social Justice publishes first volume in new book series

Retrieved on: 
Mercredi, mars 27, 2024
Employment, Series, Social justice, Thurgood Marshall College Fund, Education, Public policy, University of Southern Mississippi, Research, Hope, Social, HBCU, Investment, DRS, Future, Workforce, Gallup, Optimism, Management

Washington, D.C., March 27, 2024 (GLOBE NEWSWIRE) -- The Dr. N. Joyce Payne Center for Social Justice of the Thurgood Marshall College Fund (TMCF) recently published its first volume in The Payne Center Book Series , which focuses on pragmatic policy ideas related to social justice.

Key Points: 
  • Washington, D.C., March 27, 2024 (GLOBE NEWSWIRE) -- The Dr. N. Joyce Payne Center for Social Justice of the Thurgood Marshall College Fund (TMCF) recently published its first volume in The Payne Center Book Series , which focuses on pragmatic policy ideas related to social justice.
  • “This first volume sets the bar for the upcoming series, as we continue to examine the intersectionality of educational, economic and environmental justice in American society,” Dr. N. Joyce Payne , founder of TMCF, said.
  • The Payne Center is responsible for producing innovative social justice research; leveraging social justice research to inform public policy; supporting the research and educational missions of HBCUs; and advancing diversity, equity and inclusion in the workforce.
  • The Payne Center for Social Justice and Gallup recently released “ Black Thriving in America 2023 ,” which assessed Black life experiences in the United States and produced the groundbreaking Black American Social Justice Dashboard.

Regenx Announces Rights Offering and Share Consolidation

Retrieved on: 
Mardi, mars 26, 2024
Indian stock exchange, Exercise, Date, Corporation, Circular, Public expenditure, DRS, Eligibility, RGX, YRS, Security (finance)

Assuming the exercise of all Rights, the Rights Offering will raise gross proceeds of up to $2,966,316.

Key Points: 
  • Assuming the exercise of all Rights, the Rights Offering will raise gross proceeds of up to $2,966,316.
  • Complete details of the Rights Offering are set out in the Circular and the rights offering notice (the ‎‎“Notice”), which are filed under the Corporation’s profile at www.sedarplus.ca.
  • Registered Shareholders who wish to exercise their Rights must ‎complete and forward the Rights DRS Advice and subscription form, together with applicable funds, to Computershare Investor ‎Services Inc., the depositary for the Rights Offering, on or before the Expiry Time of the Rights Offering.
  • The proposed basis for the share consolidation is one (1) post-consolidation Common Share for up to every two (2) pre-consolidation Common Shares (the "Share Consolidation").

Factor Bioscience Expands Translational Science Team, Appoints Kyle Garland, Ph.D., as Director of Translational Science

Retrieved on: 
Mardi, avril 9, 2024
Cell engineering, Vanderbilt University, Development, Gene editing, Biotechnology, Entrepreneurship, Science, Research, Messenger, Therapy, DRS, Biological engineering, Chemical engineering, Lehigh University, Research fellow, Vaccine

CAMBRIDGE, Mass., April 9, 2024 /PRNewswire/ -- Factor Bioscience Inc. ("Factor"), a Cambridge, Massachusetts-based biotechnology company developing advanced mRNA and cell-engineering technologies, today announced the addition of three members to its translational science team, which will be led by Kyle Garland, Ph.D., who joins Factor as Director of Translational Science.

Key Points: 
  • CAMBRIDGE, Mass., April 9, 2024 /PRNewswire/ -- Factor Bioscience Inc. ("Factor"), a Cambridge, Massachusetts-based biotechnology company developing advanced mRNA and cell-engineering technologies, today announced the addition of three members to its translational science team, which will be led by Kyle Garland, Ph.D., who joins Factor as Director of Translational Science.
  • "We are excited to welcome three talented scientific professionals to Factor," said Dr. Matt Angel, Co-Founder, Chairman, and CEO of Factor.
  • "Dr. Garland, who is joined by Associate Scientists, Raven Hinkel and Elizabeth Belcher, has deep translational research expertise in mRNA and cell engineering.
  • The addition of Kyle and his team will enhance Factor's ability to support our strategic partners and accelerate our efforts to translate our technologies to new products."

Supreme Court Hears Oral Argument in Pivotal NCLA Case Against Gov’t Social Media Censorship

Retrieved on: 
Lundi, mars 18, 2024
CISA, Speech, Archive, Freedom, Ethics, COVID-19, Infection, Federation, White, Social media, Public policy, Constitution, First, Bioethics, Immunity, Kulldorff, CDC, Supreme court, DRS, Fifth, COVID-19 vaccine, Constitutional right, Safety, FBI, Injury, Paper, Government, Court, NCLA, Human

The vast, coordinated silencing of First Amendment-protected speech has targeted influential, highly qualified voices including doctors and scientists like Drs.

Key Points: 
  • The vast, coordinated silencing of First Amendment-protected speech has targeted influential, highly qualified voices including doctors and scientists like Drs.
  • We went to social media to voice our opinions and were silenced by government employees who bullied social media snowflakes into silencing our voices.
  • In the Murthy v. Missouri case, the Supreme Court has the opportunity to restore the First Amendment in this country.
  • That is what the government did here, and if that is allowed then the First Amendment is a dead letter.”

Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical Officer

Retrieved on: 
Lundi, mars 18, 2024
Sickle cell disease, University, Medicine, Doctor of Philosophy, Albireo, New Drug Application, Patient, SVP, Research, Losmapimod, Senior, Homocystinuria, Facioscapulohumeral muscular dystrophy, Therapy, DRS, Hereditary angioedema, Drug development, Interim, Boston, Fulcrum, PFIC, DSM-IV codes, Pharmaceutical industry

CAMBRIDGE, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced the appointment of Patrick Horn, M.D., Ph.D., as chief medical officer, effective immediately. Dr. Horn is a seasoned executive with over 20 years of end-to-end drug development experience spanning multiple therapeutic areas, with an emphasis on rare diseases, across both large pharmaceutical and biotech companies. Interim chief medical officer, Iain Fraser, MBChB, DPhil, will continue to serve on Fulcrum’s executive leadership team as SVP of early development. Together, Drs. Horn and Fraser will be responsible for leading clinical development and overseeing regulatory strategy and execution.

Key Points: 
  • Interim chief medical officer, Iain Fraser, MBChB, DPhil, will continue to serve on Fulcrum’s executive leadership team as SVP of early development.
  • Horn and Fraser will be responsible for leading clinical development and overseeing regulatory strategy and execution.
  • His most recent role was as the Chief Medical Officer at HemoShear Therapeutics, specializing in rare metabolic diseases.
  • Prior to transitioning to industry, Dr. Horn was a practicing pediatrician at major academic institutions in Chicago.

Molecular Partners Reports Corporate Highlights From Q4 2023 and Key Financials for Full Year 2023

Retrieved on: 
Jeudi, mars 14, 2024
CD33, GSK, Patient, Macrophage, Society, CD3, CD47, DLL3, Therapy, Molecular Partners, TME, Partner, DRS, ASH, AML, SNMMI, Partnership, RDT, Radionuclide, Tetra, Novartis, HSCT, MHS, FTE, Exposition, Delta, Safety, SITC, Amgen, Hematopoietic stem cell transplantation, FAP, Disease, Nuclear medicine, Immunotherapy, District court, Neoplasm, EANM, Alpha particle, JNJ, Tumor microenvironment, Gene family, CD70, AACR, CD40, CHF, CD123, NK, Engineering, Antigen, Molecule, Annual general meeting, Toxicity, CD16, B cell, Conference, MBA, DARPin, Data, Molecular imaging, Pharmaceutical industry

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 14, 2024 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced its corporate highlights and audited financial results for the full year 2023.

Key Points: 
  • 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced its corporate highlights and audited financial results for the full year 2023.
  • “2023 was a year of successful innovation and execution on our strategy, focusing on novel mechanisms that we believe only DARPin therapies can deliver.
  • In addition to the above updates, Molecular Partners continued to progress its RDT portfolio of projects in partnership with Novartis.
  • In the financial year 2023, Molecular Partners recognized total revenues and other income of CHF 7.0 million (2022: CHF 189.6 million) and incurred total expenses of CHF 68.1 million (2022: CHF 73.0 million).

XCath CEO Eduardo Fonseca Spotlights AI in Endovascular Robotics at SLICE Next Frontiers Conference

Retrieved on: 
Jeudi, avril 4, 2024
Neurology, General Health, Health, Artificial Intelligence, Medical Devices, Robotics, Health Technology, Technology, AI, Conference, Exhibition, DRS

XCath , an early-stage medical device company dedicated to expanding endovascular treatment modalities through its robotic systems and steerable guidewires, presented at the annual SLICE Next Frontiers Conference hosted by Dr. Vincent Costalat and Master and Fellow .

Key Points: 
  • XCath , an early-stage medical device company dedicated to expanding endovascular treatment modalities through its robotic systems and steerable guidewires, presented at the annual SLICE Next Frontiers Conference hosted by Dr. Vincent Costalat and Master and Fellow .
  • “The SLICE Next Frontiers conference convenes thought leaders from across the neuro space and is a key opportunity to learn about current innovations and where we’re going next,” said Fonseca.
  • “In conversations that took place at the event about robotics, AI and telerobotics there was a lot of enthusiasm about how these technologies can enhance patient care.
  • These objectives are all top of mind at XCath, and we look forward to being part of the future of neurovascular interventions.”
    For more information about the SLICE Next Frontiers Conference, visit https://masterandfellow.com/slice/nf .

Bioelectronic medicine Feinstein Institutes researchers elected to AIMBE College of Fellows

Retrieved on: 
Lundi, mars 25, 2024
Health, Health Insurance, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Vagus nerve, Metabolism, Interdisciplinarity, Biomedical engineering, Brain, Sepsis, Rheumatoid arthritis, Medicine, Mevalonate pathway, Interface (computing), Communication, International Society, Disease, Paralysis, Diabetes, Education, Inflammation, Pulmonary hypertension, Nervous system, Class, PNAS, Cancer, Neuroscience, Doctor of Philosophy, AIMBE, Neuron, Inflammatory Bowel Diseases, Arthritis, Credit, Northwell Health, American Institute, Molecular medicine, Sensation, Infection, DRS, Immune system, Injury, Medical research, Inflammatory bowel disease, Biology, Multimedia, National academy, Government, ISAN, Medical device

The American Institute for Medical and Biological Engineering (AIMBE) has announced the election of two researchers from The Feinstein Institutes for Medical Research to the AIMBE College of Fellows Class of 2024 for their contributions to the fields of medical and biological engineering, and particularly the field of bioelectronic medicine.

Key Points: 
  • The American Institute for Medical and Biological Engineering (AIMBE) has announced the election of two researchers from The Feinstein Institutes for Medical Research to the AIMBE College of Fellows Class of 2024 for their contributions to the fields of medical and biological engineering, and particularly the field of bioelectronic medicine.
  • Valentin Pavlov, PhD , and Sangeeta Chavan, PhD , both professors in the Institute of Bioelectronic Medicine , were recognized in-person during the AIMBE Annual Event in Washington D.C..
  • Sangeeta Chavan (left) and Valentin Pavlov (right) have been elected to the AIMBE College of Fellows for advancing the fields of medical and biological engineering.
  • On behalf of the Feinstein Institutes and Northwell Health, we congratulate them.”
    The Feinstein Institutes for Medical Research is the global scientific home of bioelectronic medicine where medical researchers use modern technology to develop new device-based therapies to treat disease and injury.